Chair: Martin Rottenberg, Karolinska Institutet, Sweden
With a great success of Myco.Tube-2023 and Mycotube-2024 we extend a cordial welcome to the 3rd International Virtual Conference on Mycobacterium tuberculosis Research and Drug Development (Myco.Tube-2026) scheduled for February 02-03, 2026, organized by United Scientific Group (A non-profit organization).
Myco.Tube-2026 promises to serve as a great platform for the exchange of knowledge, ideas, and the latest advancements in the field of Mycobacterial Infections. Together, we will explore cutting-edge research, innovative methodologies, and best practices, driving the field forward.
In this two-day conference, you will witness truly engaging featured presentations by world’s leading bacteriologists and clinicians, and a plethora of research presentations, all aimed at fostering collaborative efforts and nurturing breakthroughs in the fight against Mycobacterial Infections. The diverse range of topics covered will cater to various interests, ensuring that each participant finds valuable insights to enhance their understanding.
Beyond the scientific endeavors, Myco.Tube-2026 also offers a unique opportunity for networking and building professional relationships, engage in discussions with peers, forge new collaborations, and strengthen existing ones. The connections made during this conference often lead to groundbreaking research partnerships and collaborations that have a lasting impact.
Once again, welcome to Myco.Tube-2026! May your experience be rewarding and personally fulfilling.
We look forward to witnessing the exchange of knowledge and new ideas that will undoubtedly
shape the future of our field.
We hope that you will enjoy this conference and benefit from
networking with attendees and speakers.
Albert Einstein College of Medicine, NY, USA
Title: New Ways to Kill and Sterilize Mtb Infections
Biography(+)
As a Math Major at Edinboro State College, a small state college near Erie, Pennsylvania, Bill took a bacterial genetics course and was enamored with its power to prove causality of gene functionality. He went to the University of Alabama in Birmingham and chose to do his Ph.D with Josie Clark-Curtiss and Roy Curtiss III. Bill successfully made the first genomic libraries of Mycobacterium leprae, an organism that could only be grown in nude mouse footpads and the nine-banded armadillo. For his postdoctoral work, Bill moved to the Bronx to work with Barry Bloom to develop BCG as a vaccine vector. No one had yet been successful in transferring foreign DNA into any mycobacteria. Bill succeeded by making a chimeric shuttle vector composed of a mycobacteriophage and E. coli lambda cosmid, which he named a shuttle phasmid. Shuttle phasmids allowed for Bill’s plan to develop a complete set of genetic tools including the first plasmid transformation vectors, transposon delivery vectors, specialized transduction systems to make precise null bar-coded deletion mutants forevery gene of mycobacterium tuberculosis. Using gene transfer, Bill’s team of amazing scientists discovered the previously unknown targets of TB drugs, the primary mechanism of attenuation of BCG, and the signal transduction pathway that regulates acid-fast staining. He continues to study the phenomenon of persistence and ways the immune system can control M. tuberculosis. His lab started working on Herpes viruses 10 years ago and discovered a mutant that can protect mammals by eliciting ADCC antibodies. Bill’s lab is exploring using this Herpes vector to make new TB vaccines. Elected to the National Academy of Sciences in 2013, Bill is most proud of training over 70 young scientists with whom he has published over 350 papers and who now are actively pursuing research worldwide. He plans to discuss his lab’s current successes on 3rd generation luciferase phages. Strategies to sterilize MTB infections and efforts to dissect mammalian killing mechanisms using a novel conditionally immune sterilizable auxotroph.
University of Texas Health Houston, TX, USA
Title: TB: Diabetes interactions with old age and COVID-19
Biography(+)
Dr. Blanca I. Restrepo earned her Ph.D. in Microbiology from the University of Texas Health Science Center at San Antonio and is currently a Professor of Epidemiology at UTHealth Houston, School of Public Health in Brownsville, Texas. She has conducted pathogenesis studies involving fungi, bacteria, and helminths, and her current research focuses on tuberculosis (TB). Bilingual and bicultural, Dr. Restrepo leads multidisciplinary studies along the Texas–Mexico border to understand the epidemiologic and biological bases for the re-emerging importance of type 2 diabetes (T2D) and aging as risk factors for TB.
University of Michigan, MI, USA
Title: Assessing M. tuberculosis infection outcomes both during and after antibiotic treatment with HostSim
UMass Chan Medical School, MA, USA
Title: TBA
Biography(+)
Christopher M. Sassetti is a Professor of Microbiology at UMass Chan Medical School. He studies how Mycobacterium tuberculosis survives and causes tuberculosis in humans. His research aims to find new ways to treat and prevent TB through genetics and systems biology.
Karolinska Institute, Sweden
Title: Affinity proteomics in TB infection and disease
Biography(+)
Christopher Sundling is an associate professor at the Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet. His research group uses data-driven and conventional hypothesis-based approaches to understand host-pathogen interplay with the aim to identify novel diagnostic and immunotherapeutic targets.
Oregon Health & Science University, OR
Title: Lessons Learned from the Analysis of TCR Usage in the Context of BCG Vaccination and Exposure to Mtb
Texas Biomedical Research Institute, TX, USA
Title: Inducing host Cell Death as a Host-Directed Therapy for Tuberculosis
Biography(+)
In Dr. Larry Schlesinger’s lab, Dr. Arnett studies the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma, which is critical for M. tuberculosis growth in macrophages. Her work has identified molecules upstream of PPAR gamma activation as well as novel effectors of PPAR gamma which regulate apoptosis during M. tuberculosis infection. Apoptosis is an important defense mechanism that prevents M. tuberculosis growth, and she has found that targeting this pathway significantly reduces M. tuberculosis growth, providing new potential targets for host-directed therapy for M. tuberculosis.
Copyright ©
USG
United Scientific Group
Privacy
Policy | Terms & Conditions
myco.tube@uniscigroup.org
+1-469-854-2280/81 
USG United Scientific Group, A non-profit organization,
tbresearch.unitedscientificgroup.org/